In October 2026, the DEA administrative proceeding to reschedule marijuana from Schedule I to Schedule III remains stayed after a Government Accountability Office report identified gaps in federal drug-scheduling procedures. An administrative law judge admitted the report to the record but denied requests to reopen hearings for additional testimony, instead inviting supplemental briefs due by October 29 with replies by November 5. This follows the April 2026 final order that moved FDA-approved and state-licensed medical marijuana products to Schedule III, while the expedited hearing on broader rescheduling—including adult-use products—concluded in July with post-hearing briefs filed in August. The DEA has argued in filings that marijuana no longer meets Schedule I criteria. These procedural steps and the pending ALJ recommendation to the agency administrator represent the main near-term catalysts for trader assessments of further rescheduling timelines.